The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC Sept 2021 | Ongoing studies for datopotamab deruxtecan in NSCLC
Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, Fairfax, VA, discusses updates from the non-small cell lung cancer (NSCLC) cohort of TROPION-PanTumor01, a Phase I study evaluating datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (NCT03401385). Dato-DXd showed efficacy in patients with and without driver mutations and it is currently being assessed in a Phase II study in patients with NSCLC with actionable genomic alterations (TROPION-Lung05, NCT04484142), as well as in a Phase III study comparing Dato-DXd versus docetaxel in previously treated advanced or metastatic NSCLC without actionable genomic alterations (TROPION-Lung01, NCT04656652). Although preliminary data is highly promising, further results are eagerly awaited. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.
